Title: 3D-Printed Nanocarriers for Personalized Oral Dosing of Poorly Soluble Drugs Background: Mass-produced tablets come in fixed doses. They can't adjust for how differently one patient metabolizes a drug compared to another. Solubility is a separate, increasingly common problem: many newly developed active pharmaceutical ingredients fall into Biopharmaceutics Classification System (BCS) Class II, where the drug crosses the gut wall easily enough but dissolves too slowly to be absorbed in useful amounts. The result is poor oral bioavailability. Objective: To investigate how pharmaceutical additive manufacturing (3D printing) can combine with nanoscale drug carriers to fabricate custom oral dosage forms that overcome solubility barriers while meeting precise dosing requirements. Methodology and Core Concepts Nanocarrier Integration: Lipid-based nanoparticles and polymeric micelles encapsulate poorly water-soluble drug molecules. Beyond shielding the drug from enzymatic breakdown, this increases the effective surface area available for dissolution and slows recrystallization. That combination is what actually raises how much of the drug the gut can absorb. Additive Manufacturing Application: Computer-aided design paired with extrusion-based 3D printing, such as Fused Deposition Modeling or Semi-Solid Extrusion, builds those nanocarrier formulations into multilayered dosage units. Layer geometry and composition can be adjusted per unit, which is what makes precise, patient-specific dosing possible in the first place. Expected Outcomes and Significance: Put together, these two pieces let manufacturers produce a personalized dose on demand, with a predictable release profile and better formulation stability than the drug alone would have. That's the underlying premise: replace batches built for a population with units built for one patient. this is my abstract genrate a poster for me
Title: 3D-Printed Nanocarriers for Personalized Oral Dosing of Poorly Soluble Drugs Background: Mass-produced tablets come in fixed doses. They can't adjust for how differently one patient metabolizes a drug compared to another. Solubility is a separate, increasingly common problem: many newly developed active pharmaceutical ingredients fall into Biopharmaceutics Classification System (BCS) Class II, where the drug crosses the gut wall easily enough but dissolves too slowly to be absorbed in useful amounts. The result is poor oral bioavailability. Objective: To investigate how pharmaceutical additive manufacturing (3D printing) can combine with nanoscale drug carriers to fabricate custom oral dosage forms that overcome solubility barriers while meeting precise dosing requirements. Methodology and Core Concepts Nanocarrier Integration: Lipid-based nanoparticles and polymeric micelles encapsulate poorly water-soluble drug molecules. Beyond shielding the drug from enzymatic breakdown, this increases the effective surface area available for dissolution and slows recrystallization. That combination is what actually raises how much of the drug the gut can absorb. Additive Manufacturing Application: Computer-aided design paired with extrusion-based 3D printing, such as Fused Deposition Modeling or Semi-Solid Extrusion, builds those nanocarrier formulations into multilayered dosage units. Layer geometry and composition can be adjusted per unit, which is what makes precise, patient-specific dosing possible in the first place. Expected Outcomes and Significance: Put together, these two pieces let manufacturers produce a personalized dose on demand, with a predictable release profile and better formulation stability than the drug alone would have. That's the underlying premise: replace batches built for a population with units built for one patient. this is my abstract genrate a poster for me
Created using ChatSlide
An integrated approach combines nanocarriers with 3D printing to personalize oral medicines. By improving the solubility and absorption of poorly soluble drugs, digital design enables precise doses, tailored release profiles, and patient-specific formulations. Careful evaluation of dose accuracy, stability, and drug uniformity supports on-demand production and a shift from standardized population-based medicines to predictable, individualized therapy.